ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 224 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2022. The put-call ratio across all filers is 0.80 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $27 | +285.7% | 748 | +392.1% | 0.02% | +300.0% |
Q2 2023 | $7 | +40.0% | 152 | +16.9% | 0.01% | +25.0% |
Q1 2023 | $5 | -58.3% | 130 | -49.6% | 0.00% | -20.0% |
Q4 2022 | $12 | -99.8% | 258 | +52.7% | 0.01% | -16.7% |
Q3 2022 | $7,000 | 0.0% | 169 | +36.3% | 0.01% | 0.0% |
Q2 2022 | $7,000 | -22.2% | 124 | -0.8% | 0.01% | 0.0% |
Q1 2022 | $9,000 | +50.0% | 125 | +76.1% | 0.01% | -25.0% |
Q4 2021 | $6,000 | – | 71 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
First Light Asset Management, LLC | 213,887 | $29,608,000 | 2.19% |
Rock Springs Capital Management LP | 566,500 | $78,421,000 | 1.66% |
FEDERATED HERMES, INC. | 4,280,528 | $592,554,000 | 1.21% |
AtonRa Partners | 17,646 | $2,443,000 | 1.20% |
EMERALD MUTUAL FUND ADVISERS TRUST | 218,390 | $30,232,000 | 1.05% |
EMERALD ADVISERS, LLC | 226,875 | $31,406,000 | 1.04% |
Atika Capital Management LLC | 89,000 | $12,319,000 | 0.96% |
Capital Impact Advisors, LLC | 25,582 | $3,541,000 | 0.87% |
JGP Global Gestao de Recursos Ltda. | 1,586 | $220,000 | 0.83% |
CAPITAL INTERNATIONAL LTD /CA/ | 79,742 | $11,039,000 | 0.64% |